The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
An individualized dose/schedule strategy for sunitinib in metastatic renal cell cancer (mRCC) on progression-free survival (PFS): Correlation with dynamic microbubble ultrasound (DCE-US) data.
B. Khalil
No relevant relationships to disclose
J. M. Hudson
No relevant relationships to disclose
R. Williams
No relevant relationships to disclose
B. Lloyd
No relevant relationships to disclose
L. M. Milot
No relevant relationships to disclose
M. Atri
No relevant relationships to disclose
A. Kiss
No relevant relationships to disclose
P. Burns
Honoraria - Pfizer
G. A. Bjarnason
Honoraria - Pfizer
Research Funding - Pfizer